Predictive Financial Statements From 2010 to 2025

POAI Stock  USD 1.16  0.04  3.57%   
Predictive Oncology financial statements provide useful quarterly and yearly information to potential Predictive Oncology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Predictive Oncology financial statements helps investors assess Predictive Oncology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Predictive Oncology's valuation are summarized below:
Gross Profit
681.4 K
Market Capitalization
8.4 M
Enterprise Value Revenue
5.1758
Revenue
1.5 M
Earnings Share
(2.96)
We have found one hundred twenty available trending fundamental ratios for Predictive Oncology, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Predictive Oncology recent fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The Predictive Oncology's current Market Cap is estimated to increase to about 14.9 M. The Predictive Oncology's current Enterprise Value is estimated to increase to about 12.6 M

Predictive Oncology Total Revenue

2.15 Million

Check Predictive Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Predictive Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 954.9 K, Interest Expense of 12.9 M or Selling General Administrative of 7.1 M, as well as many indicators such as Price To Sales Ratio of 8.11, Dividend Yield of 0.0 or PTB Ratio of 1.37. Predictive financial statements analysis is a perfect complement when working with Predictive Oncology Valuation or Volatility modules.
  
Check out the analysis of Predictive Oncology Correlation against competitors.
For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.

Predictive Oncology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.5 M16.6 M10.3 M
Slightly volatile
Short and Long Term Debt Total1.9 M3.3 MM
Slightly volatile
Other Current Liabilities1.6 M1.9 M1.6 M
Slightly volatile
Total Current LiabilitiesM4.5 MM
Slightly volatile
Property Plant And Equipment Net4.8 M4.6 M1.7 M
Slightly volatile
Accounts Payable1.1 M1.5 M1.1 M
Pretty Stable
Cash10.5 M10 M5.5 M
Slightly volatile
Non Current Assets Total4.1 MM4.3 M
Slightly volatile
Cash And Short Term Investments10.5 M10 M5.6 M
Slightly volatile
Common Stock Total Equity275.4 K178.2 K329.3 K
Slightly volatile
Common Stock Shares Outstanding4.8 M4.6 M1.3 M
Slightly volatile
Liabilities And Stockholders Equity9.5 M16.6 M10.3 M
Slightly volatile
Other Current Assets630 K600 K309.1 K
Slightly volatile
Other Stockholder Equity212.5 M202.4 M89.5 M
Slightly volatile
Total Liabilities4.6 M7.1 M4.6 M
Slightly volatile
Property Plant And Equipment Gross9.1 M8.7 M2.5 M
Slightly volatile
Total Current Assets12.2 M11.6 M6.4 M
Slightly volatile
Short Term Debt1.4 M768 K1.5 M
Pretty Stable
Intangible Assets275.8 K290.3 K867.8 K
Slightly volatile
Common Stock34.7 K36.6 K361.1 K
Pretty Stable
Net Receivables270.7 K383.8 K256.3 K
Slightly volatile
Inventory299.1 K568.5 K281.2 K
Slightly volatile
Capital Surpluse70.3 M127.5 M68.6 M
Slightly volatile
Property Plant Equipment1.7 M2.4 M1.3 M
Slightly volatile
Other Liabilities21.7 K22.9 K202 K
Slightly volatile
Other Assets64.7 K68.1 K821.7 K
Slightly volatile
Net Invested Capital15.4 M9.7 M8.9 M
Slightly volatile
Short and Long Term Debt128.6 K135.4 K1.5 M
Slightly volatile
Capital Stock45.3 K47.6 K195.6 K
Pretty Stable
Capital Lease Obligations3.3 M3.1 M1.2 M
Slightly volatile
Preferred Stock Total Equity634713777
Slightly volatile
Non Current Liabilities Other4.7 K4.9 K164.9 K
Slightly volatile

Predictive Oncology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization954.9 K850.2 K980.6 K
Pretty Stable
Selling General Administrative7.1 M10.8 M7.3 M
Slightly volatile
Selling And Marketing Expenses913.9 K1.7 M958.6 K
Slightly volatile
Other Operating Expenses9.6 M18.1 M10.2 M
Slightly volatile
Total Operating Expenses9.3 M17.4 M9.9 M
Slightly volatile
Total Revenue2.1 MMM
Slightly volatile
Gross Profit1.4 M1.3 M659.1 K
Slightly volatile
Cost Of Revenue766.5 K730 K369.9 K
Slightly volatile
Research Development205.7 K216.6 K628.1 K
Pretty Stable
Reconciled Depreciation866.8 K1.1 M495.9 K
Slightly volatile
Interest Income4.4 M6.6 M3.8 M
Slightly volatile
Preferred Stock And Other Adjustments443.4 K498.9 K543.9 K
Slightly volatile
Non Recurring10.3 M11.6 M12.6 M
Slightly volatile

Predictive Oncology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow26.7 M25.4 M6.9 M
Slightly volatile
Depreciation892.7 K850.2 K466.4 K
Slightly volatile
Total Cash From Financing Activities162.7 K171.2 K7.3 M
Pretty Stable
End Period Cash Flow10.5 M10 M5.5 M
Slightly volatile
Stock Based Compensation257.8 K271.3 K2.2 M
Slightly volatile
Change To Netincome13.5 M12.9 M5.5 M
Slightly volatile
Change Receivables55.9 K62.9 K68.6 K
Slightly volatile
Dividends Paid679715B
Slightly volatile
Cash And Cash Equivalents Changes422 K474.8 K517.6 K
Slightly volatile
Cash Flows Other Operating739.8 K832.2 K907.4 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.118.5343.7871
Slightly volatile
Days Sales Outstanding12278.69115
Pretty Stable
Average Payables769.1 KM1.1 M
Pretty Stable
Stock Based Compensation To Revenue0.380.46.1041
Slightly volatile
Capex To Depreciation0.450.475.3938
Slightly volatile
EV To Sales4.54.7442.9572
Slightly volatile
Inventory Turnover1.011.161.1952
Slightly volatile
Days Of Inventory On Hand387327370
Slightly volatile
Payables Turnover0.310.430.4133
Slightly volatile
Sales General And Administrative To Revenue5.796.0917.7244
Slightly volatile
Average Inventory232 K416.2 K276.5 K
Slightly volatile
Research And Ddevelopement To Revenue0.09040.09520.5565
Very volatile
Capex To Revenue0.180.150.2633
Slightly volatile
Cash Per Share2.382.51.5 K
Slightly volatile
Days Payables Outstanding8438873.9 K
Slightly volatile
Income Quality0.460.850.599
Pretty Stable
Intangibles To Total Assets0.01910.02010.1899
Pretty Stable
Current Ratio1.362.31.9215
Slightly volatile
Receivables Turnover7.036.136.137
Very volatile
Capex Per Share0.08230.0866183
Slightly volatile
Average Receivables223 K299.2 K438.3 K
Very volatile
Revenue Per Share0.480.51337
Slightly volatile
Interest Debt Per Share0.780.822.9 K
Slightly volatile
Debt To Assets0.220.230.748
Slightly volatile
Operating Cycle509406485
Slightly volatile
Days Of Payables Outstanding8438873.9 K
Slightly volatile
Ebt Per Ebit0.860.93.4895
Pretty Stable
Quick Ratio1.32.181.8316
Slightly volatile
Net Income Per E B T1.521.621.4255
Pretty Stable
Cash Ratio1.121.991.5955
Slightly volatile
Days Of Inventory Outstanding387327370
Slightly volatile
Days Of Sales Outstanding12278.69115
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.181.0505
Slightly volatile
Fixed Asset Turnover0.490.527.0057
Slightly volatile
Debt Ratio0.220.230.748
Slightly volatile
Price Sales Ratio8.118.5343.7871
Slightly volatile
Asset Turnover0.130.140.2569
Slightly volatile
Gross Profit Margin0.470.580.5864
Slightly volatile

Predictive Oncology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap14.9 M11.9 M12.6 M
Slightly volatile
Enterprise Value12.6 M8.4 M10.3 M
Pretty Stable

Predictive Fundamental Market Drivers

Cash And Short Term Investments8.7 M

Predictive Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Predictive Oncology Financial Statements

Investors use fundamental indicators, such as Predictive Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Predictive Oncology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue354.3 K372 K
Total RevenueM2.1 M
Cost Of Revenue730 K766.5 K
Stock Based Compensation To Revenue 0.40  0.38 
Sales General And Administrative To Revenue 6.09  5.79 
Research And Ddevelopement To Revenue 0.10  0.09 
Capex To Revenue 0.15  0.18 
Revenue Per Share 0.51  0.48 
Ebit Per Revenue(7.04)(7.39)

Currently Active Assets on Macroaxis

When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:
Check out the analysis of Predictive Oncology Correlation against competitors.
For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.96)
Revenue Per Share
0.309
Quarterly Revenue Growth
(0.49)
Return On Assets
(0.66)
Return On Equity
(2.01)
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.